N,N-dibenzyl-2-chloro-9H-purin-6-amine | 496955-47-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: N,N-dibenzyl-2-chloro-9H-purin-6-amine
• 英文别名: dibenzyl-(2-chloro-9H-purin-6-yl)amine；N,N-dibenzyl-2-chloro-7H-purin-6-amine
• CAS: 496955-47-6
• 化学式: C₁₉H₁₆ClN₅
• 分子量: 349.823
• InChiKey: WWLHJEMGMGWORO-UHFFFAOYSA-N

物化性质

• 熔点：
  250-252 °C(Solv: water (7732-18-5))
• 密度：
  1.383±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  57.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N,N-dibenzyl-2-chloro-9H-purin-6-amine 在 四(三苯基膦)钯 、 potassium carbonate 作用下， 以 N-甲基吡咯烷酮 、 N,N-二甲基甲酰胺 为溶剂， 反应 20.0h， 生成 dibenzyl(2-n-butyl-9-methyl-9H-purin-6-yl)amine
  参考文献：
  名称：

  2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and Analogues as A_2A Adenosine Receptor Antagonists. Design, Synthesis, and Pharmacological Characterization

  摘要：

  Two types of adenosine receptor ligands were designed, i.e., 9H-purine and 1H-imidazo[4,5-c]pyridines, to obtain selective A(2A) antagonists, and we report here their synthesis and binding affinities for the four adenosine receptor subtypes A(1), A(2A), A(2B) and A(3). The design was carried out on the basis of the molecular modeling of a number of potent adenosine receptor antagonists described in the literature. Three compounds (25b-d) showed an interesting affinity and selectivity for the A(2A) subtype. One of them, i.e., ST1535 (2-n-butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine, 25b) (K-i A(2A) = 6.6 nM, K-i A(1)/A(2A) = 12; K-i A(2B)/A(2A) = 58; K-i A(3)/A(2A) > 160), was selected for in vivo study and shown to induce a dose-related increase in locomotor activity, suggestive of an A(2A) antagonist type of activity.

  DOI：

  10.1021/jm058018d
• 作为产物：
  描述：

  2,6-二氯嘌呤 生成 N,N-dibenzyl-2-chloro-9H-purin-6-amine
  参考文献：
  名称：

  Derivatives of triazoly-imidazopyridine useful as ligands of the adenosine A2a receptor and their use as medicaments

  摘要：

  化合物的化学式为（I），其中：X为CH或CH—R2；R1为C1-C6直链或支链烷基或C1-C6直链或支链烯基；R2为氢，C1-C6直链或支链烷基或C1-C6直链或支链烯基，C6-C14芳基或C6-C14芳基（C1-C6）直链或支链烷基或C6-C14芳基（C1-C6）直链或支链烯基，芳基基团可以选用一个或多个取代基，取代基可以相同或不同，选自卤素，羟基，C1-C6直链或支链烷氧基或C1-C6直链或支链烯氧基，氨基，可选用C1-C6直链或支链烷基单取代或双取代的氨基；R3为NH2或NHR4；R4为C1-C6烷基或C1-C6羟基烷基，C1-C3烷氧基烷基，氨基（C1-C6）烷基，其中氨基可以选择一个或两个C1-C3直链或支链烷基取代或一个或两个C2-C3烯基取代，或C6-C14芳基或C6-C14芳基（C1-C6）烷基，芳基基团可以选用一个或多个取代基，取代基可以相同或不同，选自卤素，羟基，C1-C6直链或支链烷氧基或C1-C6直链或支链烯氧基，氨基，可选用C1-C6直链或支链烷基单取代或双取代的氨基或C1-C6直链或支链烯基单取代或双取代的氨基；以及其药学上可接受的盐。这些化合物是腺苷A2a受体拮抗剂，特别适用于帕金森病的治疗。

  公开号：

  US07528252B2

文献信息

• [EN] SUBSTITUTED PURINE COMPOUNDS AS BTK INHIBITORS<br/>[FR] COMPOSÉS DE PURINE SUBSTITUÉS EN TANT QU'INHIBITEURS DE BTK
  申请人：LUPIN LTD

  公开号：WO2015151006A1

  公开（公告）日：2015-10-08

  The present invention relates to the compound of Formula (I) wherein the substituents are as described herein, and their use in a medicine for the treatment of diseases, disorders associated with the inhibition of Bruton's tyrosine kinase (BTK). It further relates to the compounds herein and their pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof useful in treating diseases, disorders, syndromes and/or conditions associated with the inhibition of BTK.

  本发明涉及式（I）的化合物，其中取代基如本文所述，并且它们在治疗与Bruton酪氨酸激酶（BTK）抑制有关的疾病、疾病和症状的药物中的用途。它进一步涉及本文中的化合物及其在治疗与BTK抑制有关的疾病、疾病、综合症和/或症状中有用的药用可接受盐，以及这些药物组合物。
• Derivatives of triazoly-imidazopyridine useful as ligands of the adenosine A2a receptor and their use as medicaments
  申请人：Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.

  公开号：US07528252B2

  公开（公告）日：2009-05-05

  Compounds of formula (I) wherein: X is CH or CH—R2; R1 is C1-C6 linear or branched alkyl or C1-C6 linear or branched alkenyl; R2 is hydrogen, C1-C6 linear or branched alkyl or C1-C6 linear or branched alkenyl, C6-C14 aryl or C6-C14 aryl(C1-C6) linear or branched alkyl or C6-C14 aryl(C1-C6) linear or branched alkenyl, with the aryl group optionally substituted by one or more substituents, either the same or different, selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy linear or branched or C1-C6 alkenyloxy linear or branched, amino, optionally mono- or disubstituted with C1-C6 linear or branched alkyl; R3 is NH2, or NHR4; R4 is C1-C6 alkyl or C1-C6 hydroxyalkyl, C1-C3 alkoxyalkyl, amino(C1-C6)alkyl, where the amino group is optionally substituted with one or two C1-C3 linear or branched alkyl groups, or with one or two C2-C3 alkenyl groups C6-C14 aryl or C6-C14 aryl(C1-C6)alkyl, with the aryl group optionally substituted by one or more substituents, either the same or different, selected from the group consisting by halogen, hydroxy, C1-C6 alkoxy linear or branched or C1-C6 alkenyloxy linear or branched, amino, mono- or di-substituted with C1-C6 alkyl linear or branched or C1-C6 alkenyl linear or branched; and their pharmaceutically acceptable salts. These compounds are antagonists of the adenosine A2a receptor and useful as medicaments, in particular for the treatment of Parkinson's disease.

  化合物的化学式为（I），其中：X为CH或CH—R2；R1为C1-C6直链或支链烷基或C1-C6直链或支链烯基；R2为氢，C1-C6直链或支链烷基或C1-C6直链或支链烯基，C6-C14芳基或C6-C14芳基（C1-C6）直链或支链烷基或C6-C14芳基（C1-C6）直链或支链烯基，芳基基团可以选用一个或多个取代基，取代基可以相同或不同，选自卤素，羟基，C1-C6直链或支链烷氧基或C1-C6直链或支链烯氧基，氨基，可选用C1-C6直链或支链烷基单取代或双取代的氨基；R3为NH2或NHR4；R4为C1-C6烷基或C1-C6羟基烷基，C1-C3烷氧基烷基，氨基（C1-C6）烷基，其中氨基可以选择一个或两个C1-C3直链或支链烷基取代或一个或两个C2-C3烯基取代，或C6-C14芳基或C6-C14芳基（C1-C6）烷基，芳基基团可以选用一个或多个取代基，取代基可以相同或不同，选自卤素，羟基，C1-C6直链或支链烷氧基或C1-C6直链或支链烯氧基，氨基，可选用C1-C6直链或支链烷基单取代或双取代的氨基或C1-C6直链或支链烯基单取代或双取代的氨基；以及其药学上可接受的盐。这些化合物是腺苷A2a受体拮抗剂，特别适用于帕金森病的治疗。
• Derivatives of triazoly-imidazopyridine and of the triazolypurines useful as ligands of the adenosine A2a receptor and their use as medicaments
  申请人：Giorgio Tarzia

  公开号：US20070249638A1

  公开（公告）日：2007-10-25

  Compounds of formula (I) wherein: X is N; R 1 is C 1 -C 6 linear or branched alkyl or C 1 -C 6 linear or branched alkenyl; R 2 is hydrogen, C 1 -C 6 linear or branched alkyl or C 1 -C 6 linear or branched alkenyl, C 6 -C 14 aryl or C 6 -C 14 aryl(C 1 -C 6 ) linear or branched alkyl or C 6 -C 14 aryl(C 1 -C 6 ) linear or branched alkenyl, with the aryl group optionally substituted by one or more substituents, either the same or different, selected from the group consisting of halogen, hydroxy, C 1 -C 6 alkoxy linear or branched or C 1 -C 6 alkenyloxy linear or branched, amino, optionally mono- or disubstituted with C 1 -C 6 linear or branched alkyl; R 3 is NH 2 , NHR 4 ; R 4 is C 1 -C 6 alkyl or C 1 -C 6 hydroxyalkyl, C 1 -C 3 alkoxyalkyl, amino(C 1 -C 6 )alkyl, where the amino group is optionally substituted with one or two C 1 -C 3 linear or branched alkyl groups, or with one or two C 2 -C 3 alkenyl groups C 6 -C 14 aryl or C 6 -C 14 aryl(C 1 -C 6 )alkyl, with the aryl group optionally substituted by one or more substituents, either the same or different, selected from the group consisting by halogen, hydroxy, C 1 -C 6 alkoxy linear or branched or C 1 -C 6 alkenyloxy linear or branched, amino, mono- or di-substituted with C 1 -C 6 alkyl linear or branched or C 1 -C 6 alkenyl linear or branched; and their pharmaceutically acceptable salts. These compounds are antagonists of the adenosine A 2a receptor and useful as medicaments, in particular for the treatment of Parkinson's disease.

  化合物的式子为(I)，其中：X为N；R1为C1-C6直链或支链烷基或C1-C6直链或支链烯基；R2为氢、C1-C6直链或支链烷基或C1-C6直链或支链烯基、C6-C14芳基或C6-C14芳基(C1-C6)直链或支链烷基或C6-C14芳基(C1-C6)直链或支链烯基，其中芳基可以选择由一个或多个取代基取代，这些取代基可以相同或不同，选自由卤素、羟基、C1-C6直链或支链烷氧基或C1-C6直链或支链烯氧基、氨基、可选择用C1-C6直链或支链烷基单取代或双取代；R3为NH2、NHR4；R4为C1-C6烷基或C1-C6羟基烷基、C1-C3烷氧基烷基、氨基(C1-C6)烷基，其中氨基可以选择用一个或两个C1-C3直链或支链烷基取代或用一个或两个C2-C3烯基取代，或C6-C14芳基或C6-C14芳基(C1-C6)烷基，其中芳基可以选择由一个或多个取代基取代，这些取代基可以相同或不同，选自卤素、羟基、C1-C6直链或支链烷氧基或C1-C6直链或支链烯氧基、氨基、可选择用C1-C6直链或支链烷基单取代或双取代或C1-C6直链或支链烯基单取代或双取代；以及它们的药学上可接受的盐。这些化合物是腺苷A2A受体拮抗剂，可用作药物，特别是用于帕金森病的治疗。
• US7230102B2
  申请人：——

  公开号：US7230102B2

  公开（公告）日：2007-06-12
• US7528252B2
  申请人：——

  公开号：US7528252B2

  公开（公告）日：2009-05-05